Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq

Roche today announced the expanded use of the VENTANA PD-L1 (SP142) Assay in triple-negative breast cancer (TNBC) for patients living in CE (Conformit é Européene) markets where the Roche cancer immunotherapy medicine Tecentriq® is approved.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news